Elspar
(Asparaginase)Phase 3Protein / enzyme
Asparaginase is used to treat certain types of leukemia and lymphoma by blocking a nutrient that cancer cells need to survive and grow.[1] Elspar is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Elspar is one of 173 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.
8
Indications
87
Total Trials
12
Active Trials
172
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia44 trials
Show 41 more trials
Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00165178·498 enrolled
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Completed·—·Phase 2·NCT00136435·100 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled
Leukemia7 trials
Acute Myeloid Leukemia7 trials
Bone Marrow Transplantation3 trials
16 more indications
Lymphoblastic Lymphoma3 trials
Recurrent B Acute Lymphoblastic Leukemia3 trials
Acute Lymphoblastic Leukaemia2 trials
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Completed·—··NCT04187248·1,248 enrolled
Myelodysplastic Syndromes2 trials
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative2 trials
Nasopharyngeal Carcinoma1 trial
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
Completed·—·N/A·NCT06676293·8 enrolled
Hypersensitivity1 trial
Allergy1 trial
B-cell acute lymphoblastic leukemia1 trial
Childhood Acute Lymphoblastic Leukemia1 trial
Treatment of Childhood Acute Lymphoblastic Leukemia
Terminated·—·Phase 3·NCT00165087·491 enrolled
Myeloproliferative Disorder1 trial
B Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- DDutch Childhood Oncology Group